


**Figure S1. Nucleoprotein-specific IgG**. IgG anti-nucleoprotein (N) titers monitored in samples collected at month 3 (M3) and 9 (M9) in each participant to the study. A negative (K-) and positive (K+) controls (WHO International Reference Panel of anti-SARS-CoV-2 immunoglobulin, NIBSC code 20/144 and 20/142 respectively) were included as reference. Antibody titres are expressed as the reciprocal of the dilution of sample reporting a double OD value compared to the background.



**Figure S2. Manual analysis of total B cells subsets**. Flow cytometry analysis of live CD19<sup>+/low</sup> B cells, according to the expression of IgD *versus* CD27 (CD27<sup>+</sup>IgD<sup>-</sup> switched memory, Ig-sw; CD27<sup>+</sup>IgD<sup>+</sup> unswitched, Unsw; CD27<sup>-</sup>IgD<sup>-</sup> double negative, DN; and CD27<sup>-</sup>IgD<sup>+</sup> *naïve*), CD21 *versus* CD27 (CD27<sup>+</sup>CD21<sup>-</sup> activated, Activ; CD27<sup>+</sup>CD21<sup>+</sup> resting, Rest; CD27<sup>-</sup>CD21<sup>-</sup> atypical, Atyp; and CD27<sup>-</sup>CD21<sup>+</sup> naïve) and IgG<sup>+</sup>, IgA<sup>+</sup>, IgD<sup>+</sup>IgM<sup>+</sup>, IgM<sup>+</sup> only.